Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2009 1
2013 1
2017 2
2018 3
2019 3
2021 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs.
Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K, Hojo S, Kawano T, Imai T. Tanaka Y, et al. Among authors: kawano t. Mod Rheumatol. 2023 Dec 22;34(1):45-49. doi: 10.1093/mr/road005. Mod Rheumatol. 2023. PMID: 36680420 Clinical Trial.
Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K, Hojo S, Kawano T, Imai T. Tanaka Y, et al. Among authors: kawano t. Arthritis Rheumatol. 2021 Apr;73(4):587-595. doi: 10.1002/art.41555. Epub 2021 Feb 18. Arthritis Rheumatol. 2021. PMID: 33038062 Free PMC article. Clinical Trial.
A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs.
Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K, Hojo S, Kawano T, Imai T. Tanaka Y, et al. Among authors: kawano t. Mod Rheumatol. 2021 Jul;31(4):783-789. doi: 10.1080/14397595.2020.1868675. Epub 2021 Feb 2. Mod Rheumatol. 2021. PMID: 33427546 Clinical Trial.
Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study.
Tabuchi H, Katsurabara T, Mori M, Aoyama M, Obara T, Yasuda N, Kawano T, Imai T, Ieiri I, Kumagai Y. Tabuchi H, et al. Among authors: kawano t. J Clin Pharmacol. 2019 May;59(5):688-701. doi: 10.1002/jcph.1361. Epub 2018 Dec 21. J Clin Pharmacol. 2019. PMID: 30575978 Clinical Trial.
Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX3 CL1/CX3 CR1 Pathway in Experimental Mouse Models of Systemic Sclerosis.
Luong VH, Utsunomiya A, Chino T, Doanh LH, Matsushita T, Obara T, Kuboi Y, Ishii N, Machinaga A, Ogasawara H, Ikeda W, Kawano T, Imai T, Oyama N, Hasegawa M. Luong VH, et al. Among authors: kawano t. Arthritis Rheumatol. 2019 Nov;71(11):1923-1934. doi: 10.1002/art.41009. Epub 2019 Sep 11. Arthritis Rheumatol. 2019. PMID: 31173491
Anti-Apoptotic Effects of Recombinant Human Hepatocyte Growth Factor on Hepatocytes Were Associated with Intrahepatic Hemorrhage Suppression Indicated by the Preservation of Prothrombin Time.
Motoi S, Toyoda H, Obara T, Ohta E, Arita Y, Negishi K, Moriya K, Kuboi Y, Soejima M, Imai T, Ido A, Tsubouchi H, Kawano T. Motoi S, et al. Among authors: kawano t. Int J Mol Sci. 2019 Apr 12;20(8):1821. doi: 10.3390/ijms20081821. Int J Mol Sci. 2019. PMID: 31013780 Free PMC article.
14 results